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Abstract
Enamel matrix derivative (EMD), an extract of fetal porcine enamel, and TGF-b can both suppress adipogenic differentiation.
However, there have been no studies that functionally link the role of EMD and TGF-b in vitro. Herein, we examined
whether TGF-b signaling contributes to EMD-induced suppression of adipogenic differentiation. Adipogenesis was studied
with 3T3-L1 preadipocytes in the presence of SB431542, an inhibitor of TGF-bRI kinase activity. SB431542 reversed the
inhibitory effect of EMD on adipogenic differentiation, based on Oil Red O staining and mRNA expression of lipid regulated
genes. SB431542 also reduced EMD-stimulated expression of connective tissue growth factor (CTGF), an autocrine inhibitor
of adipogenic differentiation. Moreover, short interfering (si)RNAs for CTGF partially reversed the EMD-induced suppression
of lipid regulated genes. We conclude that the TGF-bRI - CTGF axis is involved in the anti-adipogenic effects of EMD in vitro.
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Introduction
EmdogainH is the commercial name for the combination of
enamel matrix derivatives (EMD) isolated from the tooth germs of
6-month old piglets and the vehicle propylene glycol alginate
(PGA) (Institut Straumann, Basel, Switzerland, formerly Biora,
Malmo¨, Sweden). EmdogainH is approved to support periodontal
tissue regeneration [1]. Histological and clinical data have
indicated that the use of EmdogainH in combination with palatal
subepithelial connective tissue grafts (CTG) may enhance
periodontal wound healing/regeneration and to additionally
improve the clinical outcomes when compared to the use of
CTG alone [2–4]. Periodontal tissues and connective tissue grafts
both contain mesenchymal cells that can become adipocytes [5–7].
However, adipogenic differentiation is unwanted when a regain of
periodontal structures or the formation of a collagen-rich matrix is
desired, respectively. A first clue that EmdogainH can suppress
adipogenic differentiation comes from in vitro studies with the
mouse multipotent myoblast cell line C2C12 [8] and periodontal
ligament fibroblasts [6]. The underlying cellular mechanisms
however are poorly defined [9,10].
Transforming growth factor-beta1 (TGF-b) signaling is among
the key mechanisms that can mediate at least part of the in vitro
cellular responses to EMD and EmdogainH [11–14]. Recombinant
TGF-b inhibits adipocyte differentiation as exemplified by the
suppression of lipid droplets and the expression of adipogenic
genes such as peroxisome proliferator-activated receptor c
(PPARc), fatty acid binding protein 4 (FABP4), thrombospondin
receptor (CD36), and leukotriene C4 synthase (LTC4s) in the pre-
adipogenic 3T3-L1 clonal cell line [15,16]. TGF-b binding to type
I and type II receptor kinases (TGF-bR) activates Smad2 and
Smad3 signaling [17]. TGF-bR can also signal through mitogen-
activated protein kinases, including ERK, c-Jun N-terminal kinase
(JNK) and p38, as well the PI3K pathway [18]. Smad [19] and
mitogen-activated protein kinase [20] signaling are involved in
TGF-b -mediated inhibition of adipogenesis. Also EMD can
activate signaling via Smad2 and JNK [21]. Together, these data
led to the hypothesis that the suppression of adipogenic
differentiation by EMD may involve TGF-b signaling.
Consistent with this hypothesis is that both, TGF-b and
EmdogainH increase the expression of connective tissue growth
factor (CTGF) also known as CCN2 [14,22,23]. CTGF inhibits
adipocyte differentiation [23] and CTGF can mediate the cellular
responses to TGF-b, including the inhibition of adipocyte
differentiation [16]. Moreover, enamel matrix derivative can also
increase CTGF expression via TGF-b activity in osteoblastic cells
[14]. SB431542, a TGF-b receptor antagonist and a JNK
antagonist can inhibit CTGF expression induced by TGF-b1 in
fibroblasts [24,25]. It is thus reasonable to hypothesize that the
expected suppression of adipogenic differentiation by EMD
requires TGF-b signaling and involves CTGF expression.
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Therefore, the aim of this study was to test this hypothesis by
means of the pre-adipogenic 3T3-L1 cell line.
Materials and Methods
Adipogenic Differentiation
The 3T3-L1 murine preadipocyte cell line was kindly donated
by Christian Wolfrum ([26]; ETH Zu¨rich, Switzerland) and
cultured in a humidified atmosphere at 37uC in growth medium
consisting of DMEM (Invitrogen Corporation, Carlsbad, CA,
USA), 10% fetal calf serum (FCS; Invitrogen) and antibiotics
(Invitrogen). Mouse subcutaneous adipose tissue was obtained
from the inguinal region and cells were isolated by 0.1%
collagenase I (Sigma) digestion. Cells were plated in growth
medium at 30,000 cells/cm2 into culture dishes. The following
day, cells were incubated in growth medium containing 0.5 mM
1-methyl-3-isobutyl-xanthine (Sigma), 1 mM dexamethasone (Sig-
ma) and 1 mg/ml insulin (Calbiochem, Merck Millipore; MA). To
further stimulate adipogenesis, 10 mM indomethacin (Sigma) and
10 mM rosiglitazone (Sigma) were added to the growth medium
[27]. If not otherwise indicated, cells were cultivated for 5 days.
Test Compounds
Cells were incubated with EmdogainH at dilutions equivalent to
100 mg EMD/ml or the respective carrier propylene glycol
alginate (PGA; kindly provided by Dr. Graf; Institut Straumann
AG, Basel, Switzerland). EmdogainH containing 30 mg enamel
matrix derivative (EMD)/ml PGA (approximately 6,5% wt. PGA,
pH 3.7) and the respective vehicle were dissolved in serum-free
medium to 10 mg EMD/ml and kept a 4uC for further dilution.
For indicated experiments, EmdogainH (10 mg/ml) was heat
treated at 96uC for 3 min [28]. 3T3-L1 cells were also exposed to
EmdogainH and TGF-b for 24 hours before further cultivation in
adipogenic medium. Recombinant human (rh) TGF-b1 was
purchased from Prospec (Ness-Ziona, Israel). SB431542 (TGF-b
receptor antagonist; IC50=94 nM) and SB600125 (JNK inhibi-
tor; IC50=40–90 nM) were purchased from Santa Cruz Biotech-
nology, SCBT; Santa Cruz, CA).
TGF-b1 Enzyme Immunoassay
The immunoassay for the determination of TGF-b1 was
obtained from Enzo Life Sciences AG (Lausen, Switzerland).
Emdogain was diluted to give 1 mg EMD/ml and processed to
obtain a bioactive form that can be detected by the assay. In brief,
twenty mL of 1N HCl were added to 100 mL EMD, and after ten
minutes neutralized with 20 mL 1.2 N NaOH/0.5 M HEPES.
These samples were subjected to immunoassay and TGF-b1
concentration was calculated based on a calibration curve.
Oil Red O Staining
Cells were fixed with 10% neutral buffered formalin, washed
with 60% isopropanol, and stained with Oil Red O (0.5%; Sigma).
Cells were rinsed several times with tap water and subjected to
microscopic analysis and were photographed.
Gene Expression Analysis
Cellular RNA was isolated using an RNAqueous-Micro Kit
containing DNAse I (Ambion, Life Technologies). RNA was
quantified (Nanodrop 2000c; Thermo Scientific, Waltham, MA,
USA). Reverse transcription (RT) was performed with a high-
capacity cDNA RT-kit (Applied Biosystems, Foster City, CA) and
PCR was done with TaqManH universal PCR Master Mix
(Applied Biosystems) on a 7500 Real-Time PCR System (Applied
Biosystems). For screening, the TaqManH Array Mouse Lipid
Regulated Genes 96-well Plate (Applied Biosystems), a panel of
assays for genes controlling sterol metabolism, fatty acid metab-
olism, lipid droplet, and transcription factors was used. Further
probes were obtained from the TaqManH Gene Expression Assays
service (Applied Biosystems, Mm01184322_m1 PPARc;
Mm00521864_m1 Ltc4s; Mm00445878_m1 Fabp4;
Mm00432403_m1 Cd36; Mm01192932_g1 CTGF;
Mm01250458_m1 Alox15). For the expression of TGF-b, we
used designed primers (forward tggagcaacatgtggaactc; reverse
gtcagcagccggttacca) and SYBR Green as detection signal. The
mRNA levels were calculated by normalizing to the housekeeping
gene beta actin using the DCt method.
Western Blot Analysis
For phospho-Smad3 staining, 3T3-L1 cells were washed with
phosphate buffered saline, serum-starved for over night and then
treated with EmdogainH and TGF-b for 1 hours. For PPARc
staining, 3T3-L1 cells were grown in adipogenic medium with and
without EmdogainH for three days. Cells were lysed in SDS-buffer
containing protease inhibitors. Cell extracts were separated by
SDS-PAGE and transferred onto nitrocellulose membranes.
Membranes were blocked in a supplied buffer (LI-COR Biosci-
ences; Lincoln, NE). Binding of the antibody raised against
phospho-Smad3 (Ser423/425) (Cell Signaling Technology, Dan-
vers, MA), PPARc (E-8) and b-actin (C-4) (both SCBT) were
detected with the appropriate secondary antibody directly labeled
with near-infrared dyes and detected with the appropriate imaging
system (LI-COR Biosciences; Lincoln, NE).
Transfection with siRNA
CTGF siRNA, mock siRNA and the transfection agent were
purchased from SCBT. The transfection protocol was followed
according to the instructions of the manufacturer. Inhibition
efficacy was determined by Western blot analysis for CTGF.
Transfected cells were exposed to EmdogainH at 100 ng/ml and
TGF-b at 10 ng/ml in serum-free medium for 24 hours. Gene
expression analysis was performed targeting PPARc. Transfected
cells were also tested for their potential to provoke Oil Red O
staining of 3T3-L1 cells in the presence of EmdogainH and TGF-
b.
Statistical Analysis
Experiments were repeated at least twice and data are reported
as the mean and standard deviation. ANOVA and hoc testing
were used for analysis. Statistical significance was established at
P,0.05.
Results
EmdogainH Inhibits 3T3-L1 Adipocyte Differentiation
To investigate the impact of EmdogainH on adipocyte
differentiation, we determined the accumulation of intracellular
lipids. The 3T3-L1 cells accumulated lipid droplets within 5 days
among treatment with the adipogenic medium. Treatment of 3T3-
L1 cells with EmdogainH almost completely suppressed the
formation of lipid droplets (Figure 1A,B). Based on the TaqManH
array, EmdogainH considerably (,4-fold) decreased the mRNA
level of PPARc, FABP4, CD36, and LTC4s (Table 1). The data
were confirmed by the traditional RT-PCR approach (Figure 1C).
The decrease of PPARc by EmdogainH was also confirmed at the
protein level (Figure 1D).
EmdogainH and TGF-b also increase CTGF in 3T3-L1 cells
(Figure 1D). The TaqManH array further revealed a 20-fold
reduction of 15-lipogygenase (Alox15), which is a key enzyme
Enamel Matrix Derivative and Adipogenesis
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converting arachidonic acid to the biologically active 15(S)-HETE
[29]. However, this finding could not be confirmed by the
traditional RT-PCR approach. Together, the data show that
EmdogainH inhibits adipocyte differentiation of 3T3-L1 cells
in vitro.
Rosiglitazone and Indomethacin Failed to Rescue the
Adipocyte Differentiation of EmdogainH-treated Cells
To understand if the inhibitory effect of EmdogainH can be
overcome by manipulation of PPARc, rescue experiments with the
supplementation of indomethacin, known to increase PPARc
expression [29], and rosiglitazone, an agonist for PPARc [30],
were performed. As shown in Figure 2, indomethacin and
rosiglitazone, either alone or in combination, failed to provoke
the formation of lipid droplets in 3T3-L1 cells treated with
EmdogainH. Overall, the data show that targeting PPARc by
rosiglitazone and indomethacin cannot overcome the inhibitory
effect of EmdogainH on adipogenic differentiation.
SB-431542, an Inhibitor of TGF-b RI Kinase Activity,
Reversed the Inhibitory Effects of EmdogainH
To dissect the mechanism by which EmdogainH decreases
adipogenic differentiation of 3T3-L1 cells, we used the potent and
selective inhibitor of the TGF-b type I receptor activin receptor-
like kinase ALK5 [31]. SB-431542 allowed the formation of lipid
droplets in the presence of EmdogainH (Figure 3A). In line with
these findings, SB-431542 reversed the inhibitory effects of
EmdogainH on the mRNA level of PPARc in 3T3-L1 cells
(Figure 3B). Also in primary murine fat-derived mesenchymal
cells, SB-431542 reversed the inhibitory effects of EmdogainH and
TGF-b on the expression of adipogenic genes (data not shown).
Moreover, EmdogainH increased the mRNA levels of TGF-b by
approximately 2-fold (data not shown). Immunoassay showed
positive signals equivalent to approximately 100 ng/ml TGF- b1
in the commercial available Emdogain stock. In line with these
data, EmdogainH and TGF-b increase phosphorylation of Smad3
in 3T3-L1 cells (Figure 3C). These results suggest that TGF-b
signaling mediates the inhibitory effect of EmdogainH on
adipogenic differentiation.
EmdogainH-induced TGF-beta Signaling Cascade
Increases CTGF Expression
To further support the involvement of the TGF-b signaling
cascade, we examined the effect of EmdogainH on the expression
Figure 1. EmdogainH inhibits 3T3-L1 adipocyte differentiation. The 3T3-L1 murine preadipocytes were incubated with growth medium
containing 1-methyl-3-isobutyl-xanthine dexamethasone and insulin for 5 days in the presence of (A) propylene glycol alginate or (B) EmdogainH at
dilutions equivalent to 100 mg/ml and stained for lipid droplets. (C) EmdogainH reduced the expression of lipid regulated genes and (D) also the
signal of PPARc by Western blot analysis. EmdogainH, in contrast, increased the signal of CTGF.
doi:10.1371/journal.pone.0071046.g001
Table 1. The 3T3-L1 murine preadipocytes were incubated
with growth medium containing 1-methyl-3-isobutyl-xanthine
dexamethasone and insulin for 5 days in the presence of (A)
propylene glycol alginate or (B) EmdogainH at dilutions
equivalent to 100 mg/ml and subjected to a TaqManH Array
for Mouse Lipid Regulated Genes.
Gene ID fold upregulated Gene ID fold down regulated
Alox15 18 Soat2 2.4
Cd36 4.6 Insig1 2.5
Ltc4s 4.4 Fads3 2.5
Fabp4 4.2 Ptgs2 3.3
Pparg 3.8 Acat1 3.7
Nr1h3 3.5 Il6 4.7
Srebf1 3
Fabp5 2.8
The table indicates the genes at least 2-fold up-, or down regulated.
doi:10.1371/journal.pone.0071046.t001
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of CTGF, which is highly regulated by TGF-b, and can inhibit
adipogenesis [16,23]. EmdogainH substantially increased the
expression of CTGF in 3T3-L1 cells. Consistent with the central
role of the TGF-b signaling cascade, the presence of SB431542
but not SB600125 failed to substantially affect CTGF expression
in 3T3-L1 cells (Figure 4A). Moreover, 3T3-L1 cells transfected
with siRNA CTGF showed higher expression levels of PPARc
when exposed to EmdogainH and TGF-b. Moreover, when
transfected cells were exposed to Emdogain, a decrease of
38 kDa CTGF was observed by Western blot analysis
Figure 2. Rosiglitazone and indomethacin failed to rescue the adipocyte differentiation of EmdogainH-treated cells. The 3T3-L1
murine preadipocytes were incubated with growth medium containing indomethacin and rosiglitazone together with the basal adipogenesis-
inducing medium for 5 days in the presence of (A) propylene glycol alginate or (B) EmdogainH at dilutions equivalent to 100 mg/ml and stained for
lipid droplets.
doi:10.1371/journal.pone.0071046.g002
Figure 3. SB-431542, an inhibitor of TGF-b RI kinase activity, reversed the inhibitory effects of EmdogainH. The 3T3-L1 murine
preadipocytes were incubated with basal adipogenesis-inducing medium containing rosiglitazone and indomethacin for 5 days in the presence of
EmdogainH (100 mg/ml) or TGF-b (10 ng/ml) and a selective inhibitor of the TGF-b type I receptor SB-431542 (10 nM). (A) Lipid staining; (B) SB-431542
overcomes the blocking effect of EmdogainH on PPARc expression; (C) EmdogainH and TGF-b increase phosphorylation of Smad3 in 3T3-L1 cells.
**P,0.01%.
doi:10.1371/journal.pone.0071046.g003
Enamel Matrix Derivative and Adipogenesis
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(Figure 4C). However, siRNA CTGF could not counteract the
suppression of lipid formation by EmdogainH and TGF-b (data
not shown). These results indicate that the inhibition of adipogenic
differentiation by EmdogainH may involve an increased expression
of CTGF, at least in part by activation of TGF-b type I receptor
activity.
EmdogainH after Heating at 96uC Maintains the Ability to
Activate TGF-beta Signaling
Recent studies have shown that similar to TGF-b [28], also
heat-treatment of EmdogainH maintains a biological activity
in vitro [32]. We therefore determined whether heating up to
96uC can alter the anti-adipogenic activity of EmdogainH. As
shown in Figure 5A, heat-treated EmdogainH almost abolished the
formation of lipid droplets in 3T3-L1 cells, again being reversed by
SB431542. Moreover, heat-treated EmdogainH similarly changed
expression of PPARc and CTGF compared to unheated
EmdogainH (Figure 5B). SB431542 also reversed the effects of
heat-treated EmdogainH on PPARc and CTGF expression (data
not shown). These findings further support the role of EmdogainH
activating TGF-b RI kinase activity.
3T3-L1 Cells Retain their Adipogenic Potential after
Transient Exposure to EmdogainH
Although adipogenic differentiation of 3T3-L1 cells is sup-
pressed in the presence of EmdogainH, it is possible that the cells
regain the capacity to form adipocytes once EmdogainH has been
removed. Consistent with this idea, 3T3-L1 cells that were
exposed to EmdogainH or TGF-b for 24 and 72 hours maintain
their capacity to form lipid droplets when cultivated in the
adipogenic medium. These results demonstrate that the inhibition
of adipogenic differentiation of 3T3-L1 cells by EmdogainH is
transient (Figure 6).
Discussion
Initial studies showed that EmdogainH can suppress in vitro
adipogenic differentiation of C2C12 cells [8], periodontal ligament
fibroblasts [6] and palate fibroblasts (manuscript in preparation).
TGF-b mediating at least part of the cellular responses to
EmdogainH [11–14] is a potent inhibitor of adipocyte differenti-
ation in vitro [15,16]. The existing data raised the possibility that
the inhibitory effects of EmdogainH on adipogenic differentiation
involves TGF-b. The in vitro evidence presented here demon-
strates that blocking TGF-b RI kinase activity does indeed
overcome the inhibitory effect of EmdogainH on adipogenic
differentiation of 3T3-L1 cells. Our observation that the amount
of CTGF mRNA, a TGF-b regulated inhibitor of adipogenesis
[16,23], was also affected by EmdogainH, further supports the
central role of TGF-b RI kinase activity in the suppression of
adipogenic differentiation.
The present work is consistent with reports showing that
EmdogainH strongly increases expression of CTGF in osteogenic
cells [14] and data from microarray screening in periodontal
ligament fibroblasts [33,34], and epithelial cells [35]. It is,
however, important to note that in the present study, siRNA
CTGF only partially reduced the expression levels of PPARc
when exposed to EmdogainH and TGF-b, and that siRNA CTGF
could not counteract the suppression of lipid formation by
EmdogainH and TGF-b our observation basically supports the
involvement of the TGF-b – CTGF autocrine pathway to mediate
the inhibition of EmdogainH on adipogenesis, the definitive prove
remains open. Thus, additional work will be required to determine
whether complete blocking of CTGF can reverse the inhibitory
effect of EmdogainH on adipogenic differentiation of mesenchymal
progenitor cells in vitro.
The question arises about the source of TGF-b that mediates
the inhibition of adipogenesis in vitro. In line with our findings
that EmdogainH heated to 96uC maintains the respective
biological activity supporting observations that TGF-b is stable
under the same conditions [28]. Likewise, also heat-treatment of
EmdogainH maintains a biological activity in vitro in other studies
[32]. In support of this finding, the immunoassay detected
.100 ng TGF-b1 in the Emdogain stock, resulting in at least
1 ng TGF-b1 in the working solution. Moreover, Emdogain
caused the rapid phosphorylation of Smad3, which represents a
mainly TGF-b signaling pathway. It is, then, possible that the
inhibition of adipogenesis in our studies was the result of an
intrinsic TGF-b activity of Emdogain, similar to other reports
[10]. However, in vitro studies have suggested that EmdogainH
can increase the expression of TGF-b is various cell types [10].
These previous findings are consistent with our data that TGF-b
expression in 3T3-L1 cells is increased in response to Emdogain.
Thus, there are two possible sources of TGF-b that can contribute
to the overall inhibition of adipogenesis of mesenchymal cell in the
present report.
Mesenchymal progenitors represent a population of cells within
periodontal tissues and connective tissue grafts [5–7]. Since
Figure 4. The EmdogainH-induced TGF-b signaling cascade increases CTGF expression. (A) The 3T3-L1 murine preadipocytes were
exposed to EmdogainH (100 mg/ml) either with or without SB431542 or SB600125 for 18 hours in serum-free medium and the expression CTGF
determined. (B) 3T3-L1 cells were transfected with siRNA CTGF and the respective MOCK siRNA before being stimulated with EmdogainH or TGF-b. (C)
Inhibition of 38 kDa CTGF based on Western blot analysis.
doi:10.1371/journal.pone.0071046.g004
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histological and clinical data have indicated that the combination
of EmdogainH with palatal CTG may promote periodontal wound
healing/regeneration in recession defects [1,36,37] the question
arises, if EmdogainH affects adipogenic differentiation of mesen-
chymal progenitors in vivo. Moreover, adipose tissue-derived
mesenchymal cells are used in tissue engineering [38,39] and the
transplanted cells usually should not regain their adipogenic
phenotype. Hence, EmdogainH might serve as a potential carrier
suppressing the formation of fat cells. However, our findings that
the inhibition of adipogenesis by EmdogainH is only transient
indicate the complexity of the interpretation of our findings. The
setting of 24 hours cell incubation was chosen because also in vivo,
EmdogainH remains in place for a limited time period. Until now,
ectopic models with bone substitutes and mesenchymal cells, not
isolated from adipose tissue, either alone or together with
EmdogainH, have not reported on the differentiation of the cells
toward adipocytes [40,41]. Albeit the present study and in vitro
work from others [6,8] argue for a strong anti-adipogenic effect of
EmdogainH, the clinical relevance remains a matter of speculation.
JNK signaling can mediate EmdogainH effects in vitro [21], and
mitogen-activated protein kinase signaling is involved in TGF-b-
mediated inhibition of adipogenesis [20]. Our studies showed that
blocking of JNK signaling failed to modulate the increased
expression CTGF upon incubation of the cells with EmdogainH.
Based on this observation we propose that the classical Smad
signaling plays the key role in mediating the effect of EmdogainH
in the present study. Future studies are required to reveal the
possible activation of the Smad signaling in addition to siRNA
Figure 5. EmdogainH after heating at 966C maintains the ability to activate TGF-b signaling. (A) The 3T3-L1 murine preadipocytes were
exposed to EmdogainH (100 mg/ml) or EmdogainH previously heated up to 96uC within a basal adipogenesis-inducing medium containing
rosiglitazone and indomethacin for 5 days and lipid staining was performed. (B) 3T3-L1 cells were also exposed to normal or heat-treated EmdogainH
for 18 hours in serum-free medium before the expression of PPARc and CTGF were determined.
doi:10.1371/journal.pone.0071046.g005
Figure 6. 3T3-L1 cells retain their adipogenic potential after transient exposure to EmdogainH. The 3T3-L1 murine preadipocytes were
incubated for one day with growth medium containing EmdogainH (100 mg/ml) or TGF-b (10 ng/ml). Then the medium was replaced by basal
adipogenesis-inducing medium containing rosiglitazone and indomethacin for 5 days and lipid staining was performed.
doi:10.1371/journal.pone.0071046.g006
Enamel Matrix Derivative and Adipogenesis
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blocking of Smad 2 and Smad 3. Also the link of CTGF to signal
via fibroblast growth factor (FGF) receptors-2 is relevant as bFGF
is a antagonist for adipogenic differentiation of 3T3-L1 cells [42].
Future research perspectives might also reveal which size fraction
of EmdogainH accounts true for the inhibition of adipogenesis.
In summary, we propose that the decreased adipogenesis by
EmdogainH is caused by activation of TGF-b RI kinase in 3T3-L1
cells and is linked with a strong induction of CTGF expression.
The present in vitro findings may serve as a primer for preclinical
studies aiming to control adipogenic differentiation particularily in
the field of regenerative dentistry.
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